Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

LEUVEN, Belgium, September 11 /PRNewswire-FirstCall/ --

- ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fif
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... September 2, 2015 BiondVax Pharmaceuticals Ltd. ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... of Health and Human Services (HHS), to launch a new ... United States in the 2015-16 timeframe. The trial ... Multimeric-001 (M-001), as a primer vaccine, which would be administered ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to creating professional commercial video content, to analysis of athletic performance. Producing ... that go by too quickly to process with the naked eye. , ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... EXTON, Pa., Feb. 5 ViroPharma Incorporated,(Nasdaq: ... financial officer,and chief operating officer of ViroPharma, will ... 12:30 P.M. ET on Monday, February 11, 2008. ... New York., ViroPharma,s presentation will be webcast ...
... Feb. 5 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... meeting between Kiwa CEO and Board Chairman, ... the Department of Biology, the University of ... in research and,development (R&D) of plant growth ...
... Covance Inc. (NYSE:,CVD) today announced that it will ... Device Conference on February 6th,at 9:20 am ET. Investors ... http://www.covance.com . In order to register and download any ... with headquarters in Princeton, New Jersey, is one of ...
Cached Biology Technology:Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 2Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 3
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
(Date:8/10/2015)... The latest 364 page report from business intelligence ... border security market . Visiongain assesses that ... Now: Border security is hard to achieve and harder ... issue you need to know about - and more importantly, ... how this will impact your company and the border security ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... Chemical communication within insect species is often much more ... such as ladybird beetles, they release an alarm pheromone, ... aphids to walk around or drop from the plant. ... Letters, researchers at the University and Max-Planck-Institute in Jena, ...
... to survive, it must elude the ever vigilant immune sentinels ... if it resides in nondividing cells and doesn’t produce any ... cells. If the virus targets one of the many cell ... some viruses, like the gamma-herpesvirus, infect B cells of the ...
... gene they suspect plays an important role in triggering ... century-and-a-half ago. , And the pathogen that contains this ... the modern world?on the order of billions of dollars ... Avr3a, in a study that appears online in the ...
Cached Biology News:How A Latent Virus Eludes Immune Defenses 2How A Latent Virus Eludes Immune Defenses 3Researchers find gene that may be at root of potato blight 2Researchers find gene that may be at root of potato blight 3
ID clarifier: With ethidium bromide (50 μg/ml)...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... RNA Sample Buffer is ... buffer for experimental samples and ... sample buffer needs no dilution ... and denaturing gels. Simply mix ...
... Mouse RAW 264. 7 cells were cultured in ... at the log phase of growth. In ... forms, cells were fixed in acetone-methanol. The ... adhesive coated slide, with each wells surface specifically ...
Biology Products: